Table 1.
Clinical trials using autologous bone marrow mononuclear cells in patients with acute myocardial infarction
| Study | Study design | Cell type | Delivery method | Timing post-infarction | Adjunct procedure | Outcome |
|---|---|---|---|---|---|---|
| Meluzin et al. [93] | RCT | BMMNC | IC | 5-9 days | PCI | Dose-dependent improvement of regional myocardial function by PET |
| Fernandez-Aviles et al. [94] | NR | BMMNC | IC | 13.5 ± 5.5 days | PCI | Decrease in end systolic volume, improvement in regional and global function |
| Janssens et al. [19] | RCT | BMMNC | IC | 1 day | PCI | No effect on global LVEF, but may favourably affect infarct remodelling |
| Lunde et al. [12] (ASTAMI) | RCT | BMMNC | IC | 6 days | PCI | No effect on global LVEF |
| Schächinger et al. [17] (REPAIR-AMI) | RCT | BMMNC | IC | 3-7 days | PCI | Improvement in global LVEF |
| Ge et al. [16] | RCT | BMMNC | IC | Immediately | PCI | Improvement in LVEF |
| De Lezo et al. [95] | RCT | BMMNC or GCSF | IC | 7 days | IV fibrinolytics + PCI | Improvement in LVEF |
| Zhan-quan et al. [96] | NRC | PBSC | IC | 6 days | PCI | Improvement in LVEF |
| Wollert et al. [14] (BOOST) | RCT | BMMNC | IC | 4.8 days | PCI | Improvement in LV systolic function |
| Lipiec et al. [97] | RCT | BMMNC | IC | 4-11 days | PCI | Improvement in myocardial perfusion with no effect on global LVEF |
| Huikuri et al. [98] (FINCELL) | RCT | BMMNC | IC | 2-6 days | IV thrombolysis + PCI | Improvement in global LVEF |
| Kang et al. [99] | RCT | PBSC and GCSF | IC | PCI | Improvement in myocardial perfusion and systolic function | |
| Assmus et al. [10] (TOPCARE-AMI) | NR | BMMNC or CPC | IC | 3-7 days | PCI | Improvement in LVEF |
| Schächinger et al. [11] (TOPCARE-AMI) | NR | BMMNC or CPC | IC | 3-7 days | PCI | Improvement in EF |
| Strauer et al. [9] | NRC | BMMNC | IC | 5-9 days | PCI | Reduction in infarct region |
| Bartunek et al. [100] | NRC | BMMNC (CD133) | IC | 11.6 days | PCI | Improvement in LVEF |
| Hirsch et al. [21] | RCT | BMMNC | IC | 3-8 days | PCI | No effect on global or regional LV function |
| Tendera et al. [20] | RCT | BMMNC | IC | 3-12 days | PCI | No significant improvement in LVEF |
| Chen et al. [101] | RCT | BMMNC | IC | 18 days | PCI | Improvement in LVEF |
| Yousef et al. [15] (BALANCE) | NRC | BMMNC | IC | 7 days | PCI | Improvement in LVEF, exercise capacity and mortality |
Time from myocardial infarction to transplantation and outcomes measured are listed. ASTAMI, Autologous Stem-Cell Transplantation in Acute Myocardial Infarction; BMMNC, bone marrow-derived mononuclear cell; BOOST, Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration; CPC, circulating progenitor cell; EF, ejection fraction; GCSF, granulocyte-colony stimulating factor; IC, intracoronary; IM, intramyocardial; LVEF, left ventricular ejection fraction; NR, non-randomised; NRC, non-randomised with control group; PBSC, peripheral blood stem cell; PCI, percutaneous coronary intervention; PET, positron emission tomography; RCT, randomised controlled trial; REPAIR-AMI, Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction; TOPCARE-AMI, Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction.